6 completed, 2 recruiting, 1 active not recruiting, 1 available. 7 Phase 3, 5 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 5, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 5 | Completed 3, Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Troriluzole: new trials by email Literature Review of Troriluzole trials Research Report on Troriluzole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma Troriluzole - Glioblastoma, Recurrent Glioblastoma | Early Phase 1 | Recruiting | Ugonma Chukwueke | 27 | 2025-02-19 | 2025-09-11 |
| Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets Ipilimumab, Nivolumab, Troriluzole - Melanoma, Metastatic Melanoma | Phase 2 | Terminated | Dana-Farber Cancer Institute | 1 | 2021-06-30 | 2024-03-26 |
| A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder Troriluzole, Placebo - Obsessive-Compulsive Disorder | Phase 3 | Completed | Biohaven Pharmaceuticals, Inc. | 589 | 2021-01-29 | 2026-05-22 |
| Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder Troriluzole, Placebo - Obsessive-Compulsive Disorder | Phase 3 | Completed | Biohaven Pharmaceuticals, Inc. | 456 | 2020-12-22 | 2026-01-07 |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Temozolomide, Lomustine, Regorafenib - Glioblastoma | Phase 2 / Phase 3 | Recruiting | Global Coalition for Adaptive Research | 2250 | 2019-07-30 | 2026-11-02 |
| Troriluzole in Adult Participants With Spinocerebellar Ataxia troriluzole, Placebo - Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1 | Phase 3 | Active not recruiting | Biohaven Pharmaceuticals, Inc. | 299 | 2019-03-08 | 2026-06-24 |
| Randomized Trial of Adult Participants With Generalized Anxiety Disorder Troriluzole, Placebo - Generalized Anxiety Disorder | Phase 3 | Completed | Biohaven Pharmaceuticals, Inc. | 881 | 2019-02-19 | 2024-05-08 |
| Study of BHV-4157 in Alzheimer's Disease troriluzole, Placebo oral capsule - Alzheimer Disease | Phase 2 | Completed | Biohaven Pharmaceuticals, Inc. | 350 | 2018-07-31 | 2023-12-06 |
| Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder Troriluzole, Placebo - Obsessive-Compulsive Disorder | Phase 2 / Phase 3 | Completed | Biohaven Pharmaceuticals, Inc. | 426 | 2017-12-19 | 2026-01-22 |
| Trial in Adult Participants With Spinocerebellar Ataxia (SCA) Troriluzole, Placebo - Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1 | Phase 2 / Phase 3 | Completed | Biohaven Pharmaceuticals, Inc. | 141 | 2016-12-15 | 2025-10-08 |
| Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA) Troriluzole - SCA, Spinocerebellar Ataxias | Available | Biohaven Pharmaceuticals, Inc. | 2026-01-09 |
Obsessive-Compulsive Disorder (3) · Spinocerebellar Ataxias (3) · Glioblastoma (2) · Alzheimer Disease (1) · Ataxia (1) · Brain Neoplasms (1) · Generalized Anxiety Disorder (1) · Heart Arrest (1) · Machado-Joseph Disease (1) · Melanoma (1) · Recurrence (1) · Spinocerebellar Ataxia 10 (1) · Spinocerebellar ataxia 8 (1)
Biohaven Pharmaceuticals, Inc. (8) · Dana-Farber Cancer Institute (1) · Global Coalition for Adaptive Research (1) · Ugonma Chukwueke (1)
United States (10) · Canada (2) · China (2) · Australia (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Ann W Silk, MD, MS (1) · Tim Cloughesy, MD (1) · Ugonma Chukwueke, MD (1)
PMID 34115419, PMID 38773224, PMID 38814532, PMID 39462179, PMID 39806095, PMID 40317057, PMID 41980234